GESs with similar biological targets are often developed independently and therefore may not classify identically.
TORONTO (PRWEB) October 01, 2020
RNA gene expression signatures (GESs) offer tremendous potential to classify patients into molecular subgroups of relevance for prognostic & predictive utilities. However, GESs with similar biological targets are often developed independently and therefore may not classify identically. This, along with variations in gene expression caused by technical imprecision in the analysis process, has led to uncertainty regarding the suitability of GES for clinical trial stratification.
Almac Diagnostic Services has substantial experience in both the development & analytical validation of RNA based molecular biomarkers ensuring the assays are both robust and compliant with appropriate global regulatory frameworks for prospective clinical trial stratification.
For more information, or to register for this event, visit Overcoming the Challenges of Taking RNA Biomarkers into Clinical Trials.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.